1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington, VA: American Psychiatric Association;2013.
2. Mitchell PB, Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bull World Health Organ. 2000; 78:515–517.
3. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Purinergic dysfunction in mania: an integrative model. Med Hypotheses. 2002; 58:297–304.
Article
4. Salvadore G, Viale CI, Luckenbaugh DA, Zanatto VC, Portela LV, Souza DO, et al. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34:819–821.
Article
5. Simonato M, Varani K, Muzzolini A, Bianchi C, Beani L, Borea PA. Adenosine A1 receptors in the rat brain in the kindling model of epilepsy. Eur J Pharmacol. 1994; 265:121–124.
Article
6. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int Rev Neurobiol. 2005; 63:191–270.
Article
7. Waldeck B. Effect of caffeine on locomotor activity and central catecholamine mechanisms: a study with special reference to drug interaction. Acta Pharmacol Toxicol (Copenh). 1975; 36:Suppl 4. 1–23.
Article
8. Holmes EW, Kelley WN, Wyngaarden JB. Control of purine biosynthesis in normal and pathologic states. Bull Rheum Dis. 1975-1976; 26:848–853.
9. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol. 2001; 21:621–622.
Article
10. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry. 2008; 69:1237–1245.
Article
11. Anumonye A, Reading HW, Knight F, Ashcroft GW. Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet. 1968; 1:1290–1293.
Article
12. Painold A, Faber PL, Milz P, Reininghaus EZ, Holl AK, Letmaier M, et al. Brain electrical source imaging in manic and depressive episodes of bipolar disorder. Bipolar Disord. 2014; 16:690–702.
Article
13. Clementz BA, Sponheim SR, Iacono WG, Beiser M. Resting EEG in first-episode schizophrenia patients, bipolar psychosis patients, and their first-degree relatives. Psychophysiology. 1994; 31:486–494.
Article
14. Small JG, Milstein V, Malloy FW, Klapper MH, Golay SJ, Medlock CE. Topographic EEG studies of mania. Clin Electroencephalogr. 1998; 29:59–66.
Article
15. American Electroencephalographic Society guidelines for standard electrode position nomenclature. J Clin Neurophysiol. 1991; 8:200–202.
16. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133:429–435.
Article
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56–62.
Article
18. Hamilton M. Rating depressive patients. J Clin Psychiatry. 1980; 41(12 Pt 2):21–24.
19. Yi JS, Bae SO, Ahn YM, Park DB, Noh KS, Shin HK, et al. Validity and reliability of the Korean version of the Hamilton Depression Rating Scale(K-HDRS). J Korean Neuropsychiatr Assoc. 2005; 44:456–465.
20. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561–571.
Article
21. Hahn HM, Yum TH, Shin YW, Kim KH, Yoon DJ, Chung KJ. A standardization study of Beck Depression Inventory in Korea. J Korean Neuropsychiatr Assoc. 1986; 25:487–502.
22. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56:893–897.
Article
23. Yook SP, Kim JS. A clinical study on the Korean version of Beck Anxiety Inventory: comparative study of patient and non-patient. Korean J Clin Psychol. 1997; 16:185–197.
24. Albert U, De Cori D, Aguglia A, Barbaro F, Bogetto F, Maina G. Increased uric acid levels in bipolar disorder subjects during different phases of illness. J Affect Disord. 2015; 173:170–175.
Article
25. De Berardis D, Conti CM, Campanella D, Carano A, Di Giuseppe B, Valchera A, et al. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J Biol Regul Homeost Agents. 2008; 22:195–200.
26. Kesebir S, Tatlıdil Yaylacı E, Süner O, Gültekin BK. Uric acid levels may be a biological marker for the differentiation of unipolar and bipolar disorder: the role of affective temperament. J Affect Disord. 2014; 165:131–134.
Article
27. Gast H, Schindler K, Rummel C, Herrmann US, Roth C, Hess CW, et al. EEG correlation and power during maintenance of wakefulness test after sleep-deprivation. Clin Neurophysiol. 2011; 122:2025–2031.
Article
28. Mitra S, Nizamie SH, Goyal N, Tikka SK. Evaluation of resting state gamma power as a response marker in schizophrenia. Psychiatry Clin Neurosci. 2015; 69:630–639.
Article
29. Davidson RJ. Affective style and affective disorders: perspectives from affective neuroscience. Cogn Emot. 1998; 12:307–330.
Article
30. Henriques JB, Davidson RJ. Left frontal hypoactivation in depression. J Abnorm Psychol. 1991; 100:535–545.
Article
31. Hammond DC. Neurofeedback with anxiety and affective disorders. Child Adolesc Psychiatr Clin N Am. 2005; 14:105–123. vii
Article
32. Degabriele R, Lagopoulos J. A review of EEG and ERP studies in bipolar disorder. Acta Neuropsychiatr. 2009; 21:58–66.
Article
33. Strakowski SM, DelBello MP, Adler C, Cecil DM, Sax KW. Neuroimaging in bipolar disorder. Bipolar Disord. 2000; 2(3 Pt 1):148–164.
Article
34. Blumberg HP, Kaufman J, Martin A, Charney DS, Krystal JH, Peterson BS. Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann N Y Acad Sci. 2004; 1021:376–383.
Article